Press release
Hyperphosphatemia Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight | PUMC Pharmaceutical, Shanghai Alebund Pharmaceuticals, Ardelyx, Kyowa Kirin, Phosphate Therapeutics, Liaoning Gran
Hyperphosphatemia Pipeline
In the Hyperphosphatemia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Hyperphosphatemia NDA approvals (if any), and product development activities comprising the technology, Hyperphosphatemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Hyperphosphatemia Pipeline treatment landscape of the report, click here @ Hyperphosphatemia Pipeline Outlook- https://www.delveinsight.com/report-store/hyperphosphatemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Hyperphosphatemia Pipeline Report
• DelveInsight's Hyperphosphatemia Pipeline analysis depicts a robust space with 15+ active players working to develop 15+ pipeline treatment therapies.
• The leading companies are working in the Hyperphosphatemia market include PUMC Pharmaceutical, Shanghai Alebund Pharmaceuticals, Ardelyx, Kyowa Kirin, Phosphate Therapeutics, Liaoning Grand Nuokang Biopharmaceutical Co., Ltd., Chugai Pharmaceutical, Keryx Biopharmaceuticals, Panion & BF Biotech Inc., Sinomune Pharmaceutical, Daiichi Sankyo, J-Pharma, OPKO Renal, Altair Nanotechnologies, China Nuokang Bio-Pharmaceutical, Unicycive Therapeutics, and others.
• Promising Hyperphosphatemia Pipeline Therapies in the various stages of development include PT20, Fosrenol (Lanthanum Carbonate, BAY77-1931), KHK7791, VS-505, Sevelamer Carbonate, and others.
• On August 2023, Kyowa Kirin Co Ltd announced a study of phase 3 clinical trials for KHK7791. To investigate the safety of repeated administration of KHK7791 for 52 weeks while switching from a phosphate-binding agent to KHK7791 in Hemodialysis patients with hyperphosphatemia.
Hyperphosphatemia Overview
Hyperphosphatemia-that is, abnormally high serum phosphate levels-can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. However, even severe hyperphosphatemia is for the most part clinically asymptomatic.
For further information, refer to the detailed Hyperphosphatemia Unmet Needs, click here for Hyperphosphatemia Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/hyperphosphatemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Hyperphosphatemia Emerging Drugs Profile
• FC818 (ferric citrate): PUMC Pharmaceutical
FC818 is a novel non-calcium-based phosphate binder. One Phase I and two pivotal Phase II clinical trials showed FC818 to be an effective and safe treatment for lowering and/or maintaining serum phosphorus levels
• VS 505: Shanghai Alebund Pharmaceuticals
VS 505 is a phosphate binding modulator being developed by Shanghai Alebund Pharmaceuticals for the treatment of Hyperphosphataemia. The drug is currently in phase II of clinical trials.
Hyperphosphatemia Pipeline Therapeutics Assessment
There are approx. 15+ key companies which are developing the therapies for Hyperphosphatemia. The Hyperphosphatemia companies which have their Hyperphosphatemia drug candidates in the most advanced stage, i.e. phase III include, PUMC Pharmaceutical.
Request a sample and discover the recent advances in Hyperphosphatemia Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Hyperphosphatemia Segmentation- https://www.delveinsight.com/sample-request/hyperphosphatemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Hyperphosphatemia Drugs and Companies
• PA21: Kissei Pharmaceuticals
• Tenapanor: Ardelyx
• VS-505: Shanghai Alebund Pharmaceuticals Limited
Hyperphosphatemia Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Hyperphosphatemia Therapeutics Market include-
PUMC Pharmaceutical, Shanghai Alebund Pharmaceuticals, Ardelyx, Kyowa Kirin, Phosphate Therapeutics, Liaoning Grand Nuokang Biopharmaceutical Co., Ltd., Chugai Pharmaceutical, Keryx Biopharmaceuticals, Panion & BF Biotech Inc., Sinomune Pharmaceutical, Daiichi Sankyo, J-Pharma, OPKO Renal, Altair Nanotechnologies, China Nuokang Bio-Pharmaceutical, Unicycive Therapeutics, and others.
Dive deep into rich insights for drugs for Hyperphosphatemia Pipeline, click here @ Hyperphosphatemia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/hyperphosphatemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Hyperphosphatemia Pipeline Report
• Coverage- Global
• Hyperphosphatemia Companies- PUMC Pharmaceutical, Shanghai Alebund Pharmaceuticals, Ardelyx, Kyowa Kirin, Phosphate Therapeutics, Liaoning Grand Nuokang Biopharmaceutical Co., Ltd., Chugai Pharmaceutical, Keryx Biopharmaceuticals, Panion & BF Biotech Inc., Sinomune Pharmaceutical, Daiichi Sankyo, J-Pharma, OPKO Renal, Altair Nanotechnologies, China Nuokang Bio-Pharmaceutical, Unicycive Therapeutics, and others.
• Hyperphosphatemia Therapies- PT20, Fosrenol (Lanthanum Carbonate, BAY77-1931), KHK7791, VS-505, Sevelamer Carbonate, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Hyperphosphatemia Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/hyperphosphatemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Hyperphosphatemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hyperphosphatemia - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Hyperphosphatemia Collaboration Deals
9. Late Stage Products (Phase III)
10. FC 818: PUMC Pharmaceutical
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. VS 505: Shanghai Alebund Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Hyperphosphatemia Key Companies
17. Hyperphosphatemia Key Products
18. Hyperphosphatemia- Unmet Needs
19. Hyperphosphatemia- Market Drivers and Barriers
20. Hyperphosphatemia- Future Perspectives and Conclusion
21. Hyperphosphatemia Analyst Views
22. Hyperphosphatemia Key Companies
23. Appendix
Trending Reports:
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Ambulatory Arrhythmia Monitoring Devices Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Choroidal Neovascularization Market: https://www.delveinsight.com/report-store/choroidal-neovascularization-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Cardiopulmonary Bypass Equipment Market: https://www.delveinsight.com/report-store/cardiopulmonary-bypass-equipment-market
• Chemotherapy Induced Anemia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Clbp Market: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/infographics/pemphigus-vulgaris-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Calciphylaxis Market: https://www.delveinsight.com/report-store/calciphylaxis-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Inflammtory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Cutaneous T-cell Lymphoma Market: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market
Contact Info:
Ankit Nigam
Assistant Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperphosphatemia Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight | PUMC Pharmaceutical, Shanghai Alebund Pharmaceuticals, Ardelyx, Kyowa Kirin, Phosphate Therapeutics, Liaoning Gran here
News-ID: 3469032 • Views: …
More Releases from DelveInsight Business Research
Chemotherapy Induced Nausea and Vomiting Pipeline 2025: Therapies Under Investig …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chemotherapy Induced Nausea and Vomiting pipeline constitutes 4+ key companies continuously working towards developing 6+ Chemotherapy Induced Nausea and Vomiting treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Chemotherapy Induced Nausea and Vomiting Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical…
Desmoid Tumors Market to Expand Significantly by 2034, States DelveInsight Repor …
DelveInsight's "Desmoid Tumors Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Desmoid Tumors, historical and forecasted epidemiology as well as the Desmoid Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Desmoid Tumors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Desmoid Tumors Market Forecast
https://www.delveinsight.com/sample-request/desmoid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key…
Extensive-Stage Small Cell Lung Cancer Pipeline 2025: MOA, ROA, FDA-Approved Dru …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Extensive-Stage Small Cell Lung Cancer pipeline constitutes 25+ key companies continuously working towards developing 30+ Extensive-Stage Small Cell Lung Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Extensive-Stage Small Cell Lung Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and…
Pancreatic Cancer Market Growth Projections 2024-2034: DelveInsight Analysis
The Pancreatic Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Pancreatic Cancer market dynamics.
DelveInsight's "Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of Pancreatic Cancer, historical and forecasted epidemiology as well as the Pancreatic Cancer market trends in the United States, EU5 (Germany,…
More Releases for Hyperphosphatemia
Key Trends Reshaping the Hyperphosphatemia Treatment Market: Rising Emphasis On …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Hyperphosphatemia Treatment Market Size Growth Forecast: What to Expect by 2025?
The market size for hyperphosphatemia treatment has seen a swift expansion in the recent past. The projected growth is from $4.56 billion in 2024 to $5.08 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.4%.…
Sustainable Growth Of Hyperphosphatemia Treatment Market Amid Rising Chronic Dis …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
What Will the Hyperphosphatemia Treatment Industry Market Size Be by 2025?
The market for hyperphosphatemia treatment has expanded quickly in recent years. Its size is set to increase from $4.56 billion in 2024 to $5.13 billion in 2025, with a compound annual growth rate (CAGR) of 12.4%. The extension during the historical period is…
Key Influencer in the Hyperphosphatemia Treatment Market 2025: Sustainable Growt …
What industry-specific factors are fueling the growth of the hyperphosphatemia treatment market?
The rise in chronic illnesses among patients is boosting the hyperphosphatemia treatment market. Conditions like cardiovascular and kidney diseases, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer all fall under the category of chronic diseases, which are non-communicable and demand long-term management. For instance, the World Health Organization reported in September 2023 that 74% of the 41 million global deaths…
Hyperphosphatemia Pipeline Insight Report 2024
(Albany, United States) As per DelveInsight's assessment, globally, the Hyperphosphatemia Pipeline constitutes 15+ key companies continuously working towards developing 15+ Hyperphosphatemia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Hyperphosphatemia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Hyperphosphatemia NDA approvals (if any), and product development activities comprising…
Hyperphosphatemia Drugs Market to Witness Robust Expansion by 2029
The Hyperphosphatemia Drugs Market size is expected to grow at an annual average of CAGR 2% during the forecast period (2023-2029). Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic uncontrolled diabetes, and low…
Hyperphosphatemia- Market Insight, Epidemiology and Market Forecast -2030
Hyperphosphatemia Market research report is the new statistical data source added by Infinity Business Insights.
Hyperphosphatemia is a condition in which your blood contains a lot of phosphate (or phosphorus). Phosphate is an electrolyte, a chemically charged compound containing the mineral phosphorus. Phosphate is required by your body to strengthen your bones and teeth, create energy, and construct cell membranes. Phosphate, on the other hand, in excess can cause bone…
